| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
196.93(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,622 |
| 52
Week Range: |
$1.32 - $4.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 5.2 |
| Insider 3/6 Months : 9.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,500 |
4,000 |
5,598 |
32,898 |
| Total Buy Value |
$10,840 |
$11,733 |
$14,587 |
$57,671 |
| Total People Bought |
2 |
3 |
3 |
5 |
| Total Buy Transactions |
2 |
3 |
4 |
11 |
| Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
| Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Czirr James C |
Director |
– • • |
2021-01-04 |
4 |
AS |
$2.23 |
$22,300 |
D/D |
(10,000) |
6,346,440 |
|
90% |
|
| Lewis Joel |
President and CEO |
• • – |
2020-12-31 |
4 |
A |
$2.24 |
$16,666 |
D/D |
7,440 |
157,411 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-12-15 |
4 |
A |
$2.52 |
$16,667 |
D/D |
6,614 |
149,971 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-11-30 |
4 |
A |
$2.60 |
$16,666 |
D/D |
6,410 |
143,357 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-11-13 |
4 |
A |
$2.75 |
$16,668 |
D/D |
6,061 |
136,947 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-10-30 |
4 |
A |
$2.54 |
$16,667 |
D/D |
6,562 |
130,886 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-10-15 |
4 |
A |
$2.87 |
$16,666 |
D/D |
5,807 |
124,324 |
|
- |
|
| 10x Capital Management, Llc |
10% Owner |
– – • |
2020-10-13 |
4 |
S |
$2.97 |
$29,700 |
D/D |
(10,000) |
6,356,440 |
|
17% |
|
| Lewis Joel |
President and CEO |
• • – |
2020-09-30 |
4 |
A |
$2.67 |
$16,666 |
D/D |
6,242 |
118,517 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2020-09-15 |
4 |
A |
$2.93 |
$15,151 |
D/D |
5,171 |
112,275 |
|
- |
|
| Freeman Kevin D |
Director |
– • – |
2020-09-04 |
4 |
B |
$2.57 |
$12,848 |
I/I |
5,000 |
25,000 |
2.1 |
-18% |
|
| Uihlein Richard E |
Director |
– • • |
2020-09-04 |
4 |
B |
$2.55 |
$25,500 |
D/D |
10,000 |
7,893,191 |
3.92 |
-18% |
|
| Zordani Richard A. Jr. |
Director |
– • – |
2020-08-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,583 |
|
-16% |
|
| Freeman Kevin D |
Director |
– • – |
2020-03-19 |
4 |
B |
$1.64 |
$9,844 |
I/I |
6,000 |
20,000 |
2.1 |
65% |
|
| Uihlein Richard E |
Director |
– • • |
2020-02-13 |
4 |
OE |
$2.39 |
$200,003 |
D/D |
65,513 |
7,883,191 |
|
- |
|
| Lewis Joel |
Director |
– • – |
2020-02-09 |
4 |
OE |
$2.39 |
$19,120 |
D/D |
8,000 |
107,104 |
|
- |
|
| Lewis Joel |
Director |
– • – |
2020-01-09 |
4 |
A |
$2.86 |
$58,501 |
D/D |
20,455 |
99,104 |
|
- |
|
| Uihlein Richard E |
Director |
– • • |
2020-01-09 |
4 |
A |
$2.86 |
$35,001 |
D/D |
12,238 |
7,817,678 |
|
- |
|
| Freeman Kevin D |
Director |
– • – |
2019-11-15 |
4 |
B |
$3.36 |
$10,076 |
I/I |
3,000 |
14,000 |
2.1 |
- |
|
| Czirr James C |
Managing Member of GP |
– – – |
2019-10-10 |
4 |
S |
$3.73 |
$63,325 |
D/D |
(17,000) |
6,385,790 |
|
- |
|
| Freeman Kevin D |
Director |
– • – |
2019-09-06 |
4 |
B |
$3.71 |
$4,786 |
I/I |
1,290 |
11,000 |
2.1 |
- |
|
| Amelio Gilbert F |
Director |
– • – |
2019-09-05 |
4 |
S |
$3.30 |
$99,000 |
D/D |
(30,000) |
124,614 |
|
- |
|
| Czirr James C |
Managing Member of GP |
– – – |
2019-08-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(38,690) |
6,402,790 |
|
- |
|
| Czirr James C |
Managing Member of GP |
– – – |
2019-07-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(306) |
6,441,480 |
|
- |
|
| Shlevin Harold H. |
Chief Executive Officer |
• – – |
2019-06-04 |
4 |
OE |
$1.37 |
$11,927 |
D/D |
8,706 |
8,706 |
|
- |
|
516 Records found
|
|
Page 6 of 21 |
|
|
0.05 (1.43%) 
